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Background: During HIV infection and/or antiretroviral therapy (ART), monocytes and macrophages exhibit a wide
range of dysfunctions which contribute significantly to HIV pathogenesis and therapy-associated complications.
Nevertheless, the molecular components which contribute to these dysfunctions remain elusive. We therefore
applied a parallel approach of genome-wide microarray analysis and focused gene expression profiling on
monocytes from patients in different stages of HIV infection and/or ART to further characterise these dysfunctions.
Results: Processes involved in apoptosis, cell cycle, lipid metabolism, proteasome function, protein trafficking and
transcriptional regulation were identified as areas of monocyte dysfunction during HIV infection. Individual genes
potentially contributing to these monocyte dysfunctions included several novel factors. One of these is the
adipocytokine NAMPT/visfatin, which we show to be capable of inhibiting HIV at an early step in its life cycle.
Roughly half of all genes identified were restored to control levels under ART, while the others represented a
persistent dysregulation. Additionally, several candidate biomarkers (in particular CCL1 and CYP2C19) for the
development of the abacavir hypersensitivity reaction were suggested.
Conclusions: Previously described areas of monocyte dysfunction during HIV infection were confirmed, and novel
themes were identified. Furthermore, individual genes associated with these dysfunctions and with ART-associated
disorders were pinpointed. These genes form a useful basis for further functional studies concerning the
contribution of monocytes/macrophages to HIV pathogenesis. One such gene, NAMPT/visfatin, represents a
possible novel restriction factor for HIV.
Background
Both macrophages and T lymphocyte subsets express
the CD4 receptor and either the CXCR4 and/or the
CCR5 coreceptor which confer susceptibility to infection
with the Human Immunodeficiency Virus (HIV). Upon
infection, CD4
+ T lymphocytes typically succumb to the
cytopathic effect of the virus [1], and the gradual deple-
tion of the CD4
+ T lymphocyte pool has been consid-
ered a hallmark of HIV infection and the development
of the Acquired Immune Deficiency Syndrome (AIDS)
since the early days of the HIV pandemic. Macrophages,
on the other hand, do not tend to suffer from the cyto-
pathic effects mediated by the virus [2,3], but instead
develop a wide array of dysfunctions which contribute
significantly to the pathogenesis of HIV infection.
Despite the recognition of macrophage contribution to
HIV pathogenesis early on in HIV research [4,5], most
studies have focused and continue to focus on T lym-
phocyte depletion and/or dysfunction, and many of the
molecular mechanisms underlying the macrophage dys-
function during HIV infection remain poorly charac-
terised. Nevertheless, as pointed out by other authors
[6], in the combination Antiretroviral Therapy (ART)
era where viral suppression in T lymphocytes is increas-
i n g l ym o r ee f f i c i e n t ,t h eu n d e r s t a n d i n go ft h ev i r a l
mechanisms in other reservoir cells such as macro-
phages becomes ever more crucial.
Aberrant HIV-induced macrophage behaviour can be
classified as relatively straightforward loss of function,
such as reduced phagocytosis [7,8] and antigen presen-
tation [9], or as more complex dysfunction. Such dys-
functions include a direct contribution to the
establishment, spread and persistence of the infection: * Correspondence: rvdbergh@vub.ac.be
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spread dissemination and a persistent failure to enter
apoptosis upon infection [10,11], they represent an
important cellular reservoir for the virus [12]. Addition-
ally, macrophages exacerbate disease progression by
contributing to T lymphocyte depletion: HIV infected
macrophages have been documented to participate in
the killing of uninfected CD4
+ and CD8
+ Tl y m p h o -
cytes, while at the same time protecting infected CD4
+
T lymphocytes from apoptosis [13]. Furthermore,
infected and uninfected macrophages can contribute to
sustained chronic immune activation during HIV infec-
tion, e.g. through the perturbation of cytokine and che-
mokine networks [14-16]. With the acknowledged
notion of chronic immune activation as a paradoxical
driving force of immune suppression [17], this pro-
inflammatory macrophage phenotype during HIV infec-
tion may be a crucial parameter in disease progression.
Yet other macrophage dysfunctions are associated with
more peripheral HIV- or ART-associated disorders such
as atherosclerosis [18], lipodystrophy [19], and metabolic
syndrome during HIV infection and/or combination
ART [20,21].
Monocytes, for their part, are much less permissive to
infection with HIV, both in vitro [22] and in vivo, where
estimates of infected circulating monocytes are consis-
tently low [23,24]. Circulating monocytes represent the
most accessible primary model for macrophage dysfunc-
tion during HIV infection, however, and are furthermore
of sufficient importance to study in their own right.
Infectious virus can be recovered from circulating
monocytes, both in untreated patients [24] and in
patients undergoing long-term successful combination
ART [25]. Additionally, the circulating monocyte pool
as a whole does seem to be affected during HIV infec-
tion, despite the low frequency of actually infected
monocytes. Transcriptome studies, in particular, show a
form of hybrid phenotype exhibiting both increased and
decreased pro-inflammatory features [26,27]. This mod-
ulation of the non-infected monocyte population could
be due to the virus itself through mechanisms which do
not require direct infection [28], or to other factors con-
tributing to (aberrant) immune activation occurring dur-
ing HIV infection, such as perturbed cytokine networks
[29] or other inflammatory stimulants [30].
Several key factors in the described dysregulated pro-
cesses have been identified [18,31], but many molecular
components remain elusive. Furthermore, other aspects
of HIV and combination ART pathogenesis in which
monocyte/macrophage dysfunction is involved may only
now be emerging or remain yet to be discovered, in par-
ticular in view of the limited number of studies focuss-
ing on the monocyte response to ART [32]. In order to
generate novel hypotheses rather than test pre-existing
ones in the context of monocyte-HIV interactions, we
performed a transcriptome analysis on monocyte sam-
ples from patients in different stages of HIV infection
and/or combination ART treatment, using a parallel
approach of genome-wide microarray analysis and
focused gene expression profiling to identify broad areas
of monocyte dysfunction and to pinpoint genes which
are potentially involved in one or several of these dys-
functions. In particular the factors which are exploited
by the monocyte/macrophage to communicate with
and/or modulate other immune cells were of interest, as
they represent a particularly relevant population [33,34]
which is a primary target for intervention.
Methods
Sample collection
For the cross-sectional study on the effects of HIV
infection, 50 ml blood samples were collected in EDTA-
tubes from therapy-naïve HIV-1-seropositive patients
from the HIV-Clinic of the Institute of Tropical Medi-
cine in Antwerp, Belgium (inclusion of all therapy-naïve
seropositive patients, irrespective of viral load (VL) and/
or CD4
+ T lymphocyte (CD4T) count; n = 29). For the
longitudinal study on the effects of combination ART,
20 ml blood samples were collected in EDTA-tubes
from therapy-naïve patients at baseline and at 3, 6 and 9
months after therapy initiation (NRTI+PI regimen only).
In all patients but one the indication for ART was a
decline in CD4T ≤ 350 cell/mm>
3;i r r e s p e c t i v eo fV L( n
= 16). As controls, 50 ml blood samples were collected
in EDTA-tubes from self-asserted HIV seronegative
blood donors without apparent infections, in the same
age range as the HIV patients (n = 15). The study was
approved by the Institutional Review Board of the Insti-
tute of Tropical Medicine, and written informed consent
was obtained from all donors. Patient characteristics are
shown in table 1 (cross-sectional) and table 2
(longitudinal).
Peripheral blood mononuclear cells (PBMC’s) were
separated by Lymphoprep (Axis Shield, Dundee, United
Kingdom) gradient. Monocytes were purified from the
PBMC fraction using the negative selection-based
Monocyte Isolation Kit II from Miltenyi-Biotec (Ber-
gisch Gladbach, Germany), according to the manufac-
turer’s instructions. Yields were minimally 5 million
monocytes with a purity > 85%, as verified through flow
cytometry. For RNA extraction, monocytes were imme-
diately lysed in Trizol (Invitrogen, Carlsbad, CA, USA)
and lysates were stored at -80°C.
RNA and protein isolation
Total RNA was prepared from Trizol lysates by chloro-
form extraction, as per the manufacturer’s recommenda-
tions. Ten randomly selected samples were checked for
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no contamination or degradation of RNA was detected.
Subsequently, the protein fraction was purified from the
Trizol pellets by isopropanol precipitation, again accord-
ing to the manufacturer’s instructions.
CodeLink arrays
Selected RNA samples were prepared and hybridised to
CodeLink HWG bioarrays (Amersham Biosciences, Frei-
berg, Germany; now Applied Microarrays, Tempe, AZ,
USA - http://www.appliedmicroarrays.com) by the VIB
MicroArray Facility http://www.microarrays.be. Total
RNA was controlled for integrity and purity using an
Agilent Bioanalyzer and a NanoDrop spectrophot-
ometer, respectively. All samples were of similar RNA
quality. Starting with 1 μgo ft o t a lR N A ,t h eR N A
amplification was performed by in vitro transcription
(IVT) with a biotin labeling reaction during the IVT,
according to the recommendations of the manufacturer
(Amersham Biosciences). A set of bacterial control
mRNAs was added to the RNA as controls for the IVT
reaction. The probes were purified and analyzed again
for yield (> 20 μg) and purity (260:280 nm and 260:230
nm > 1.8). 10 μg of the resulting antisense RNA was
Table 1 Clinical information of therapy-naïve HIV-1 seropositive donors (cross-sectional study)
Patient ID Experiment CD4T count
(cells/mm
3)




TN 01 MAS & CL 133 2.70 TN 16 MAS 503 4.32
TN 02 MAS & CL 142 2.28 TN 17 MAS 532 4.78
TN 03 MAS & CL 197 5.91 TN 18 MAS 535 4.78
TN 04 MAS 226 5.59 TN 19 MAS 540 4.36
TN 05 MAS 233 5.59 TN 20 MAS & CL 644 4.34
TN 06 MAS 311 4.97 TN 21 MAS 738 5.58
TN 07 MAS 329 5.37 TN 22 MAS 746 4.90
TN 08 MAS & CL 359 3.87 TN 23 MAS & CL 748 5.54
TN 09 MAS 359 5.84 TN 24 MAS 756 5.07
TN 10 MAS 371 3.60 TN 25 MAS 760 3.93
TN 11 MAS 374 4.24 TN 26 MAS 778 5.00
TN 12 MAS 382 4.00 TN 27 MAS 781 3.50
TN 13 MAS 436 4.28 TN 28 MAS & CL 856 4.82
TN 14 MAS & CL 446 3.91 TN 29 MAS 1026 3.08
TN 15 MAS 462 4.06
Table 2 Clinical information of HIV-1 seropositive donors on combination ART (longitudinal study)
CD4T count (cells/mm
3) VL (log copies/ml)
Patient ID Experiment BL M3 M6 M9 BL M3 M6 M9
HA 01 MAS 239 373 407 502 4.61 2.37 < 1.70 < 1.70
HA 02 MAS 153 222 353 263 5.36 1.75 1.85 < 1.70
HA 03 MAS 193 441 446 437 5.36 2.84 1.72 2.05
HA 04 MAS 273 608 577 761 4.58 < 1.70 < 1.70 < 1.70
HA 05 MAS 548 592 956 778 4.88 2.12 < 1.70 < 1.70
HA 06 MAS 239 317 348 591 5.01 < 2.60 < 1.70 < 1.70
HA 07 MAS 165 209 282 222 5.13 < 2.60 < 2.60 < 1.70
HA 08 MAS 146 241 264 315 4.48 < 1.70 < 1.70 < 1.70
HA 09 MAS 205 ND 400 318 5.45 ND < 1.70 < 1.70
HA 10 MAS 269 327 451 372 5.26 < 1.70 < 1.70 < 1.70
HA 11 MAS 324 707 561 590 5.68 3.26 < 2.60 < 2.60
HA 12 MAS 202 245 254 242 5.16 < 1.70 < 1.70 < 1.70
HA 13 MAS 261 ND 425 432 5.77 ND < 1.70 < 1.70
HA 14 MAS 318 257 270 338 5.14 < 1.70 < 1.70 < 1.70
HA 15 MAS 258 524 462 300 4.57 2.35 < 1.70 < 1.70
HA 16 MAS 232 356 358 318 5.57 < 2.60 3.85 < 1.70
MAS: custom Macrophage Activation State array platform; CL: commercial CodeLink HWG bioarray platform; CD4T: CD4
+ T lymphocyte; VL: viral load; BL: baseline;
M3/6/9: sample taken resp. 3, 6 and 9 months after therapy initiation; ND: not done.
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manufacturer (Amersham Biosciences) and resuspended
in 260 μl of hybridization buffer.
The gene array chips were hybridized in a shaker-
incubator at 37°C at 300 rpm for 18 hours and washed
and stained with Cy5-Streptavidin according to the
recommendations of the manufacturer (Amersham Bios-
ciences). The DNA Microarray scanner of Agilent was
used for scanning and image analysis was performed
with the Codelink Expression Analysis 4.1 software.
Datasets were deposited at the EMBL-EBI repository
(accession E-MEXP-2255).
Macrophage Activation State arrays
The Macrophage Activation State (MAS) array was
developed as a focused and flexible tool for the analysis
of gene expression patterns in monocytes/macrophages
(manuscript in preparation). A collection of genes (ca.
700) associated with different macrophage activation
states was compiled, using a combination of literature
data-mining and human ‘translation’ of murine models
of macrophage activation available in our laboratory (the
complete gene population represented on this array is
documented in Additional file 1). Subsequently, gene
specific primers were designed for the genes in this col-
lection and fragments were amplified from total cDNA
pools of monocytes under various in vitro and in vivo
conditions. These fragments were applied in duplicate
on 7 × 10 cm nylon membranes and were cross-linked
to the membranes using UV-exposure.
RNA samples from all patients were selected for ana-
lysis on this MAS array. A reverse transcription was per-
formed on 1 μg total RNA using oligo-dT and
Superscript II reverse transcriptase (Invitrogen) in the
presence of
33P-dCTP (Amersham Biosciences), and the
labelled cDNA was then hybridised to the membranes
for 20 h at 42°C in NorthernMax hybridisation buffer
(Ambion, Austin, TX, USA). Membranes were subse-
quently washed with SDS-containing buffer at 68°C and
were exposed to a phosphorscreen to reveal bound
radioactivity. Phosphorscreens were then scanned in a
phospho-imager (BioRad). Spot recognition and quanti-
fication, background correction and array normalisation
were performed using custom-designed software based
on the program ImageJ (Image Processing and Analysis
in Java, Sun Microsystems, Santa Clara, CA, USA).
Real-time semi-quantitative PCR
mRNA expression of the individual genes of interest was
examined using real-time semi-quantitative PCR (RT-
qPCR). cDNA was prepared from 1 μgt o t a lR N Au s i n g
oligo-dT and Superscript II reverse transcriptase (Invi-
trogen). Gene specific primers for the genes of interest
and the housekeeping gene GAPDH (Entrez GeneID:
2597) were used to run PCR reactions in duplicate in a
BioRad MyCycler, with BioRad iQ SYBR Green Super-
mix. Gene expression was normalised using GAPDH as
a housekeeping gene. Sequences of the gene specific pri-
mers are supplied as Additional file 2.
In vitro infection experiments
For in vitro infection experiments, PBMC’s were sepa-
rated by Lymphoprep (Axis Shield, Dundee, United
Kingdom) gradient from buffy coats of healthy donors
of the Blood
Transfusion Centre of Antwerp and were either
employed as such in PBMC infection experiments or
were used for monocyte preparation. Monocytes were
purified from PBMC by magnetic isolation using CD14
microbeads (Miltenyi-Biotec) according to the manufac-
turer’s instructions. Yields were minimally 50 million
monocytes with a purity > 98%, as verified through flow
cytometry. These cells were then differentiated to mono-
cyte-derived macrophages (MDM) during 7 days in
RPMI 1640 medium (Bio-Whittaker, Verviers, Belgium)
supplemented with 10% bovine fetal calf serum (Bio-
chrom, Berlin, Germany), penicillin (100 U/ml) and
streptomycin (100 μg/ml) (Roche) and 40 ng/ml M-CSF
(PeproTech, London, United Kingdom) at 37°C and
5.0% CO2. Half of the medium was replaced after 4 days
of culture. Cells were harvested and used for experi-
ments in the same medium (without M-CSF). All
experiments were repeated with cells from three inde-
pendent donors.
V i r u ss t o c k s( H I V BaL,H I V 968-2 and HIV968-3)w e r e
prepared by short-term propagation in PHA/IL2-stimu-
lated PBMC from HIV seronegative donors as described
previously [35].
Recombinant factors (CCL2, NAMPT and PDGFC)
were obtained from PeproTech; viability of cells trea-
ted with the recombinant factors was evaluated using
the cell proliferation agent WST-1 (Roche) according
to the manufacturer’s instructions: no appreciable
effect on cell viability was observed at the concentra-
tions used (data not shown). For infections, MDM or
non-activated PBMC were plated in 96-well plates at
7.5 × 10
5 cells/ml and pre-treated with recombinant
CCL2 (20 ng/ml), NAMPT (100 ng/ml) or PDGFC (20
ng/ml) for 24 hours at 37°C and 5.0% CO2.T h e n ,a
dilution series of virus was added in sixfold and incu-
bated for 24 hours, again at 37°C and 5.0% CO2.C e l l s
were then washed 3 × to remove unbound virus and
incubated for 14 days in the presence of 5 ng/ml IL2
(Roche) and 0.5 μg/ml phytohemagglutinin (PHA;
Murex Biotech Ltd., Dartford, United Kingdom) for
PBMC and in complete medium without cytokines for
macrophages. Productive infection was monitored via
an in-house developed p24 antigen ELISA, as described
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TCID50 (50% tissue culture infectious dose) value,
which was calculated by the method of Reed &
Muench [36]. For viral binding experiments, the same
procedure was followed (pre-incubation with NAMPT
of 4 hours instead of 24 hours), but cells were incu-
bated with the virus for 2 hours and were then lysed
in 200 μl NP40 solution after washing. p24 content of
the lysate was then assessed by ELISA to quantify the
bound virus.
For proviral quantification experiments, MDM or
non-activated PBMC were plated in 24-well plates at 1
×1 0
6 cells/ml and pre-treated with recombinant visfatin
(200 ng/ml) for 24 hours at 37°C and 5.0% CO2.T h e n ,
virus was added at a multiplicity of infection of 0.1 and
0.001 and incubated for 24, again at 37°C and 5.0%
CO2. Cells were then immediately lysed in Trizol (Invi-
trogen) and genomic DNA was prepared from the Tri-
zol pellets as per the manufacturer’s recommendations.
Proviral DNA levels were determined semi-quantita-
tively by RT-qPCR: gene specific primers for the viral
LTR region (LTR_NEC152: 5’-GCCTCAATAAA
GCTTGCCTTGA-3’ and LTR_NEC131: 5’-GGCGC
CACTGCTAGAGATTTT-3’) and the genomic house-
keeping fragment ERV-3 (PHP10-F: 5’-CATGGGAAG-
CAAGGGAACTAATG-3’ and PHP10-R: 5’-CCCAGC
GAGCAATACAGAATTT-3’)w e r eu s e dt or u nP C R
reactions in duplicate in a BioRad MyCycler, with
BioRad iQ SYBR Green Supermix. Proviral DNA was
normalised using ERV-3 as a housekeeping gene, as dis-
cussed elsewhere [37].
Nampt-Elisa
An ELISA kit for NAMPT/visfatin (AdipoGen, Seoul,
Korea) was used for NAMPT detection, as suggested by
Körner and colleagues [38]. Plasma samples (undiluted)
of HIV patients and healthy control donors were ana-
lysed according to the manufacturer’s instructions.
NAMPT-Western Blot
Total cellular NAMPT was detected by Enhanced Che-
moluminescence (ECL) Western Blot. 30 μgs a m p l e s
were run on a 10% SDS-PAGE gel and transferred to
PVDF membranes using the iBlot Dry Blotting System
(Invitrogen) according to the manufacturer’si n s t r u c -
tions. A rabbit anti-NAMPT polyclonal Ab (Bethyl
Laboratories, Montgomery, TX, US) at 1:3000 dilution
and an an anti-rabbit-HRP conjugate (Sigma-Aldrich,
Saint Louis, MO, US) at 1:10000 dilution were used to
probe these membranes. The membranes were subse-
quently incubated for 5 minutes with SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL,
US) and exposed to photosensitive film. Films were
developed using a Fujifilm FPM-100A developer
(Fujifilm, Tokyo, Japan). After exposure, the membranes
were incubated in 50% H2O2 to saturate the bound HRP
and were reprobed in the same fashion for the house-
keeping protein b-actin.
In vitro assessment of NAMPT activity
MDM generated as described above, plated in 96-well
plates at 7.5 × 10
5 cells/ml, were stimulated with
NAMPT (200 ng/ml) and E. coli lipopolysaccharide
(LPS) (100 ng/ml) for 2 days. Secretion of the b-chemo-
kines MIP1a (CCL3), MIP1b (CCL4) and RANTES
(CCL5) was assessed by Cytometric Bead Assay (CBA)
(Becton Dickinson, Erembodegem, Belgium) in cell cul-
ture supernatants according to the manufacturer’s
instructions. Additionally, CCR5 and CXCR4 expression
on stimulated MDM was assessed in flow cytometry as
described previously [39].
Statistical analysis
All microarray datasets were processed using the Gene-
Maths XT software package (Applied Maths, St.-Mar-
tens-Latem, Belgium).
For CodeLink HWG bioarrays, all genes were re-anno-
tated (i.e. updating of replaced Gene ID’s, etc.) using the
22.01.2009 releases of the Entrez and UniGene data-
bases. A dataset was compiled after background correc-
tion (subtract algorithm) and array normalisation (mean
algorithm). A set of differentially expressed genes was
compiled by filtering the data according to three criteria:
(1) statistical significance: p-value as determined by
Student’s t test < 0.01 (or for a more stringent analysis:
p-value after Benjamini-Hochberg correction [40] for
FDR control < 0.1); (2) reliability:as p o tq u a l i t yf l a gG
("good”, a quality flag assigned by the CodeLink software
package) in all arrays and (3) relevance: a fold change
between the means of the two groups ≥ 1.5.
Overrepresentation analysis was performed on pro-
cessed CodeLink datasets using the application Gene
Map Annotator and Pathway Profiler (GenMAPP) [41]
v.2.1 and the associated program MAPPFinder [42] v.2
(based on the Gene Ontology (GO) annotations pro-
vided by the GO Consortium[43]). Pathways which were
identified by these software packages were subjected to
filtering criteria: (1) number of “changed” (i.e. signifi-
cantly differentially expressed) genes in a pathway ≥ 3;
(2) z-score ≥ 1.96 and (3) permute p-value ≤ 0.05.
For MAS arrays, datasets were compiled as mentioned
above. Sets of differentially expressed genes were com-
piled by filtering the data according to (1) statistical
significance: p-value as determined by an uncorrected
Mann-Whitney test < 0.05 (for the cross-sectional
study) or a p-value < 0.05 in ANOVA (for the longitudi-
nal study); (2) reliability: variation between spot repli-
cates ≤ 20% and (3) relevance: a fold change between
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baseline versus ART timepoints) ≥ 1.5. The error rate
was estimated by RT-qPCR and training/comparison set
validation, using the cross-sectional study as training set
and the baseline samples of the longitudinal study as
comparison set. For the smaller population sizes in the
analysis of genes associated with the abacavir hypersen-
sitivity reaction, an uncorrected Student’st - t e s ta n da
m o r es t r i n g e n tf o l dc h a n g ec u t - o f fo f2 . 5w e r eu s e dt o
identify differentially expressed genes.
Correlation of gene expression with viral load and/or
CD4T count was assessed via Spearman correlation test.
All viral infection data are expressed as mean ± SEM;
representative data of at least three independent experi-
ments are shown, except where indicated. NAMPT
expression data and plasma loads were assessed by non-
parametric Mann-Whitney test.
Results
Identification of perturbed gene networks in monocytes
of therapy-naïve HIV patients
To identify the areas of monocyte dysfunction in our
patient population, eight therapy-naïve HIV patient sam-
ples and four healthy control samples (table 1) were
selected for analysis on CodeLink HWG microarrays.
Samples with a broad range of CD4T counts
representative for the full patient population, and
healthy controls in the same age range, were chosen.
While the sample number in this preliminary experi-
ment was too low to identify reliable individual biomar-
kers with sufficient statistical power, these datasets can
be used to distinguish the broad cellular processes or
pathways which are modulated as a whole by HIV infec-
tion. Samples were grouped according to HIV sero-sta-
tus, i.e. no stratifications according to CD4T count or
viral load were performed. A collection of 91 differen-
tially expressed genes (172 using the less stringent con-
ditions) was compiled (supplied as Additional file 3).
The processed datasets were then analysed using Gen-
MAPP and MAPPFinder to identify the global biological
trends in our expression data. This over representation
analysis revealed a set of processes which appear to be
modulated/dysregulated to a significant degree in mono-
cytes of therapy-naïve HIV patients (table 3). The most
specific GO term which is still significant is shown: i.e.
when for example “regulation of transcription” and its
daughter term “negative regulation of transcription” are
called as significant, we show only this second term.
Several of these processes, such as transcriptional regu-
lation and cell cycle modulation, were previously identi-
fied in other transcriptome studies as modulated by HIV
in monocytes and monocyte-derived macrophages
Table 3 Overrepresentation of biological processes in differential gene expression data of monocytes from therapy-
naïve HIV patients





induction of apoptosis 6917 2.622 0.03
response to radiation 9314 3.198 0.017
Cell cycle
cell maturation 48469 3.862 0.006
positive regulation of cell proliferation 8284 3.062 0.009
Lipid Metabolism
Hs_Adipogenesis User 2.896 0.018
Proteasome activity
cysteine-type endopeptidase activity 4197 4.486 0.009
Proteolysis 6508 1.996 0.044
ubiquitin cycle 6512 2.271 0.041
ubiquitin-protein ligase activity 4842 2.527 0.05
Protein trafficking
protein import into nucleus 6606 4.732 0.001
Transcriptional regulation
DNA binding 3677 2.929 0.003
negative regulation of transcription 16481 3.207 0.012
transcription regulator activity 30528 2.534 0.017
negative regulation of transcription\, DNA-dependent 45892 2.422 0.038
GO: Gene Ontology;
1: the official GO identification code for the process http://www.geneontology.org, “User” denotes a user contributed pathway;
2: the score
for the standard statistical test under the hypergeometrical distribution, as calculated by MAPPFinder;
3: the permute p-value as correction on the z-score, as
calculated by MAPPFinder; GO terms shown in boldface were identified using both the stringent and less stringent criteria, other terms were only found using
the less stringent criteria.
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metabolism and proteasome function, have been linked
with HIV-monocyte/macrophage interactions [18,44],
but were to the best of our knowledge not yet described
in the context of a transcriptome analysis. Establishment
of these broad areas of gene dysregulation in monocytes
during HIV infection allowed us to classify genes in our
subsequent analyses.
Focused transcriptome profiling of monocytes of therapy-
naïve and combination ART-treated HIV patients
In parallel with this pathway-finding approach, we
attempted to identify individual differentially
expressed genes in a cross-sectional study of therapy-
naïve HIV patients and in a longitudinal study of HIV
patients on combination ART (table 1&2) using our
custom MAS array platform. The cross-sectional
group of therapy-naïve HIV patients was used as a
training set: the gene expression in this population (n
= 29) was compared with the expression in healthy
control samples (n = 15) in order to identify genes
with a differential expression between the groups,
using our filtering criteria described above (signifi-
cance/reliability/relevance). Furthermore, subgroups
of patients with a high plasma viral load (VL ≥ 5l o g
copies/ml, n = 9) and/or a low CD4 T count (CD4 T
≤ 400 cells/mm
3, n = 12) only were also compared
with healthy control samples. The genes passing our
selection (31 transcripts or 30 genes) were validated
by RT-qPCR. Gene normalisation was performed
using GAPDH expression. While several studies have
suggested that GAPDH is suboptimal as a housekeep-
ing gene in specific models (e.g. [45]) and that the
enzymatic pathway in which it is involved may be
modulated by HIV infection [46], our own analyses
on several archetypal housekeeping genes indicated
that GAPDH was stably expressed across all samples
(not shown). In this way, we were able to compile a
collection of genes (29 transcripts, 28 genes) for
which the expression was associated with HIV seros-
tatus in the training set of therapy-naïve samples.
This collection of genes was then validated against the
comparison set of baseline samples of the longitudinal
study, which were analysed in the same fashion (MAS
array profiling followed by RT-qPCR confirmation). 26
transcripts (25 genes) passed this validation (Figure 1A,
references [47-57]), while 6 additional genes were found
in the comparison set which were not identified in the
training set. Furthermore, in the training set two addi-
tional genes were identified only in patients with high
VL and/or low CD4T count (Figure 1B), while in the
comparison set two genes modulated exclusively by
therapy were identified by ANOVA (Figure 1C, refer-
ence [58]). For 14 of these transcripts expression was
restored to control levels, while for 12 the expression
remained dysregulated after 9 months of combination
ART. An overview of the different classes of genes is
presented in table 4.
Identification of genes associated with the abacavir
hypersensitivity reaction
In the longitudinal arm of this study, we observed a
hypersensitivity reaction to the drug abacavir in two out
of seven patients, at the time unscreened for HLA-
B*5701, who were receiving abacavir as a component of
their combination ART regimen. Using our MAS array
dataset, we compared monocyte gene expression pat-
terns at baseline between patients with the hypersensi-
tivity reaction and patients on the same regimen
without adverse effects. We identified 6 genes which
appear to be differentially expressed between patients
who develop the abacavir hypersensitivity reaction and
patients who do not: the cytoplasmic enzymes CA2 and
CYP2C19, the chemokine CCL1, the transcription factor
NFIB, and the transmembrane receptor NRP2 were
upregulated in these patients, while the uncharacterised
nuclear factor ANP32E was downregulated (Additional
file 4). While these results lack statistical power due to
the small population sizes, they are indicative of trends
which may be of particular interest in the context of
monocyte involvement in the hypersensitivity reaction
or in the pursuit of biomarkers with diagnostic or prog-
nostic value.
Upregulation of an innate immune factor with inhibitory
capacities against HIV
As mentioned previously, we were particularly interested
in secreted factors which are used by the monocyte/
macrophage to modulate their own activity or that of
other immune cells. Out of the secreted factors modu-
lated in the therapy-naïve HIV patients, CCL2 (also
known as MCP-1, Entrez GeneID 6347), NAMPT (also
known as visfatin or PBEF1, Entrez GeneID 10135) and
PDGFC (also known as fallotein, Entrez GeneID 56034),
were found to be correlated with the viral load in ther-
apy-naïve patients (Figure 2A-C) and for CCL2 a correla-
tion with the CD4T count was also observed (Figure 2D).
As a first step to evaluate the putative contribution of
these factors to HIV infection, non-activated PBMC and
MDM were pre-treated with these factors and then
infected with the HIV lab strain BaL. For two out of the
three factors, CCL2 and PDGFC, inconsistent effects
between individuals were observed in both PBMC and
MDM. The novel adipocytokine NAMPT, however, sig-
nificantly inhibited HIVBaL infection in all donors in both
cell-types (Figure 3A-B). Upon further examination,
NAMPT was also capable of inhibiting the biological
clones HIV968-3 and HIV968-2 [59] (Figure 3C), suggesting
Van den Bergh et al. Retrovirology 2010, 7:53
http://www.retrovirology.com/content/7/1/53
Page 7 of 16Figure 1 Genes identified by transcriptome analysis in monocytes of HIV patients versus healthy controls. A) Genes passing RT-qPCR
and training/comparison set validation; mean fold change between the comparison set and healthy controls as assessed by RT-qPCR is shown
at baseline and at 3, 6 and 9 months of therapy.
1: the Official Gene Symbol (OGS, Entrez Gene);
2: the Entrez Gene identification code;
3:
Classification system (evidence for these classifications was derived from the Gene Ontology annotations, except where indicated); B) Genes
identified only in patients with CD4T ≤ 400 cells/mm
3 and/or VL ≥ 5 log copies/ml; mean fold change between the comparison set and healthy
controls as assessed by RT-qPCR is shown at baseline and at 3, 6 and 9 months of therapy. C) Genes identified by ANOVA as differentially
regulated during therapy; mean fold change between the comparison set and healthy controls as assessed by RT-qPCR is shown at baseline and
at 3, 6 and 9 months of therapy.
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Page 8 of 16Table 4 Classification of differentially expressed genes in monocytes of therapy-naïve and combination ART-treated
HIV patients








Down NR0B2 8431 IL1F7 27178 GAS6 2621
MAFF 23764 ADORA2A 135 CAPZA1 829
SLC11A1 6556 CCL23 6368






Up PTGER2 5732 CD83 9308
KLF10 7071 HLA-DRA 3122
FCGR3A 2214 BCL6 604
CDKN1A 1026
MARCKS 4082
STAT1 isoform - a 6772




1: the Official Gene Symbol (OGS, Entrez Gene);
2: the Entrez Gene identification code. Genes encoding secreted factors are shown in boldface.
Figure 2 A-C) Correlation of mRNA gene expression in monocytes of therapy-naïve HIV patients, as assessed by RT-qPCR, with the
viral load; D) Correlation of mRNA gene expression in monocytes of therapy-naïve HIV patients, as assessed by RT-qPCR, with the
CD4
+ T lymphocyte count - p-values for Spearman correlation testing are shown.
Van den Bergh et al. Retrovirology 2010, 7:53
http://www.retrovirology.com/content/7/1/53
Page 9 of 16that the induction of this factor in monocytes during HIV
infection could represent a hitherto unknown innate
antiviral response. As plasma levels (Figure 4A) and total
monocyte protein expression of NAMPT (Figure 4B)
were also found to be elevated in HIV patients but not in
patients on > 9 months combination ART, mirroring the
mRNA expression levels, this factor may be of in vivo
relevance during HIV infection.
NAMPT interferes with early events of the viral life cycle
To evaluate at which level the effect of NAMPT may be
acting, integration of proviral DNA in presence and
absence of NAMPT was measured semi-quantitatively
in HIVBaL-infected MDM and PBMC. NAMPT treat-
ment managed to decrease the integration of proviral
DNA in infected cultures (Figure 5A), suggesting that
NAMPT interferes with early, pre-integration events of
the viral life cycle. As viral binding and entry into the
cell is a likely target of inhibi t o r yf a c t o r s ,w ea s s e s s e d
whether NAMPT could block viral interaction with the
cell. While a modest reduction of HIV attachment to
MDM was observed in a crude viral binding assay (Fig-
ure 5B), inhibition of infectivity was not due to modula-
tion of CD4 (not shown) or the CCR5 coreceptor
(Figure 5C) or induction of the b-chemokines MIP1a,
MIP-1b and RANTES (Figure 5D), suggestive of a novel
inhibitory mechanism.
Discussion
Despite a clearly established role of monocytes and
macrophages in the pathogenesis of HIV infection, the
molecular mechanisms and genetic networks underpin-
ning the myeloid dysfunctions during HIV infection
have remained elusive. Using a combined approach of
genome-wide microarray analysis and focused mono-
cyte/macrophage-specific gene expression profiling, we
Figure 3 Modulation of viral infectivity of the lab-attenuated
strain HIVBaL by the secreted factors CCL2, NAMPT and PDGFC:
infection of A) PBMC and B) MDM (pre-)treated with
recombinant factors by HIVBaL. C) Modulation of the viral
infectivity of the biological clones HIV968-2 and HIV968-3 by the
secreted factor NAMPT in PBMC and MDM. TCID50 values were
determined using the method of Reed & Muench[36], based on p24
measurement in culture supernatants. Infectivity in treated cells is
expressed as a percentage of infectivity in untreated control cells.
Results in 3 independent donors are shown.
Figure 4 A) Plasma levels of NAMPT versus therapy status, as
assessed by ELISA (nControl = 13, nTherapy-naïve = 24, nART = 19);
B) Total NAMPT protein expression in monocytes of therapy-naïve
HIV patients (VL ≥ 4 log copies/ml), normalised to b-actin
expression, as assessed by ECL-Western Blot (nControl = 15, nTherapy-
naïve = 28). p-values calculated by nonparametric Mann-Whitney test;
n.s.: not significant, ART: antiretroviral therapy.
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Page 10 of 16attempted to identify genes which may contribute to the
HIV-associated monocyte dysfunction in vivo.
Using a commercial genome-wide microarray platform
we identified several biological processes which were
significantly modulated by HIV infection. These pro-
cesses include both previously documented pathways in
the context of monocyte-HIV interactions, such as cell
cycle modulation and apoptotic pathways, and processes
hitherto not identified in this context by transcriptome
profiling, such as lipid metabolism, protein trafficking
and proteasome function. Our gene expression data are
supported by previously documented in vitro studies in
these domains [18,44].
A custom monocyte/macrophage-focused gene expres-
sion profiling platform combined with RT-qPCR valida-
tion was used to identify individual genes of interest in
different areas of dysfunction in monocytes of therapy-
naïve and ART-treated HIV patients. This approach was
chosen for its higher cost-effectiveness and increased
experimental flexibility versus a commercial microarray
setup (manuscript in preparation). Our datasets reflect
an aberrant immune activation of monocytes/macro-
phages which may be of considerable relevance for HIV
pathogenesis. Specifically, we observe suppression of a
cluster of factors involved in chemotaxis, suggesting an
important deficiency at the level of immune cell recruit-
ment in monocytes of HIV infected patients (table 5).
Other immune response-associated genes are downregu-
lated as well, indicative of a deficient monocyte activa-
tion state: PLA2G7, the IL1-like cytokine IL1F7 and the
ion transporter SLC11A1, commonly known as Natural
Resistance Associated Macrophage Protein or NRAMP1.
On the other hand, the downregulation of ADORA2A
and LILRB4, and the upregulation of PTGER2, IFI30,
STAT1, CD83, BCL6 and NAMPT are suggestive of an
activated phenotype. Our results are therefore in accor-
dance with observations concerning a mixed phenotype
of both increased and decreased pro-inflammatory fea-
tures [26,27] which does not seem to be restored com-
pletely during at least the first 9 months of combination
ART. A longer period of combination ART may be
required to normalise this phenotype, or it may repre-
s e n tat r u ei r r e v e r s i b l ei m m u n ed y s f u n c t i o ni nt h e
monocyte population.
Most of the genes in our collection can be clustered in
the functional categories identified in the genome-wide
analysis. As such, our approach differs from other tran-
scriptome analyses, in that we identify candidate genes
for further analysis in a broad range of categories, rather
than focussing on particular aspects of monocyte/
macrophage dysfunction [26,27,60]. These clusterings
are summarised in table 5.
Figure 5 A) Levels of integrated proviral DNA in MDM and
resting PBMC (pre-)treated with NAMPT (200 ng/ml) and
infected with HIVBaL at 0.1 and 0.001 MOI, normalised to ERV-
3, as assessed by RT-qPCR; B) viral binding to MDM, as quantified
by p24 concentrations in cell lysates after 2 hours incubation and
washing of the unbound virus; C) expression of CCR5 and CXCR4
on MDM treated 2 days with NAMPT (200 ng/ml) and LPS (100 ng/
ml), as assessed by flow cytometry[39]; D) secretion of the b-
chemokines MIP1a, MIP1b and RANTES by MDM treated 2
days with NAMPT (200 ng/ml) and LPS (100 ng/ml), as
assessed by CBA. MFI: mean fluorescence intensity.
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Page 11 of 16In the context of apoptosis/DNA damage for example,
w ei d e n t i f yac l u s t e ro fg e n e sw h i c hm a yc o n t r i b u t et o
the anti-apoptotic gene signature described in mono-
cytes of HIV infected patients [15,60]. A cluster of fac-
tors which is capable of mediating apoptotic triggers in
trans on other cells, thus contributing to lymphocyte
depletion, was also identified. A similar cluster of genes
possibly involved in HIV-driven cell cycle modulation
[61] and multiple genes in the context of the broad bio-
logical terms protein trafficking and transcriptional reg-
ulation, reflecting the general subversion of the cellular
machinery for viral purposes, were also described (table
5).
Specifically in the context of metabolic disorders, our
results support the growing notion that metabolic dysre-
gulation in the context of HIV infection is probably not
limited to the phase under ART, but is a pre-existing
condition, manifesting sub-clinically during therapy-
naïve HIV infection [62,63]. We have indeed identified a
set of genes dysregulated by HIV itself which may be
capable of modulating lipid metabolism. Downregulation
of the nuclear factor NR0B2 can via several intermedi-
aries increase the catabolism of cholesterol [64]. Down-
regulation of the acetylhydrolase PLA2G7 may result in
an increased risk for atherosclerosis, though the role of
this enzyme in this field is still contentious. The
decreased expression of CCR2 [65] and increased
expression of NAMPT [66,67] may impact on athero-
sclerotic lesion formation. In the context of ART-asso-
ciated complications, finally, we have identified several
genes which are reported to be linked with lipodystro-
phy and/or the metabolic syndrome as modulated under
ART (CAPZA1 [68], CCL2 [69], GAS6 [70], NAMPT
[71,72], STAT1 [73]), suggesting that the monocyte
population may contribute to the development of ART-
associated metabolic disorders through these factors.
Additionally, the genes identified in our study may of
course play unexpected roles in other manifestations of
monocyte/macrophage dysfunction. Because of the
interesting properties of secreted factors, which repre-
sent the means by which monocytes/macrophages can
mediate many of their effects in autocrine or paracrine
fashion [29,33,34], we focused on three factors which we
identified as differential and which showed an associa-
tion with the viral load in therapy-naïve HIV patients.
For two factors, CCL2 and PDGFC, no consistent effects
were observed on HIV infectivity in PBMC and MDM.
For the novel adipocytokine NAMPT/visfatin, however,
an inhibitory effect was observed on HIV infection in
both cell types for both a lab-attenuated strain and two
biological clones. NAMPT may thus represent an (inter-
feron-induced) antiviral factor which is elicited in
response to higher levels of circulating virus. Indeed, in
silico profiling of NAMPT expression using the web
application Genevestigator [74] suggests that it is upre-
gulated in multiple models of viral infection, including
infections with CMV, measles virus, herpes simplex
virus, rotavirus and adenoviruses.
NAMPT appears to act on early events of the viral life
cycle, as the integration of proviral DNA is abrogated by
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Page 12 of 16NAMPT treatment. A plausible mechanism for the inhi-
bitory activity of NAMPT would therefore be blocking
of viral binding to the cell; indeed, binding of HIV is
reduced in the presence of NAMPT. However, the
observed modest reduction may suggest that viral bind-
ing is not the only or even the most important factor in
NAMPT activity. Additionally neither modulation of
(co-)receptor expression or induction of b-chemokine
secretion by visfatin could be demonstrated. Possible
other aspects of viral binding and/or post-entry/pre-
integration effects remain to be evaluated. In this regard,
the role of NAMPT in TNF regulation through its func-
tion in cellular energy metabolism [75] seems a promis-
ing research avenue.
Finally, we analysed the gene expression patterns in
monocytes from patients who developed a hypersensitiv-
ity reaction to abacavir, a severe and potentially lethal
adverse reaction to the drug. Compelling evidence for
the involvement of antigen presenting cells in general
and monocytes in particular in the development of the
abacavir hypersensitivity reaction was recently published
[76]. Six genes were identified as differentially expressed
at baseline between patients who developed the hyper-
sensitivity reaction and patients who were initiated on
the same regimen and had a beneficial response. These
genes may provide a first basis for investigations aimed
at the identifying bio-markers for the development of
the abacavir hypersensitivity reaction. This could be
especially useful in populations where the HLA-B*5701
genotypic screening lacks predictive value [77]. Further-
more, they may play an important role in the molecular
mechanisms underlying this detrimental form of immu-
nopathology. Two genes in particular may be of func-
tional interest: upregulation of CYP2C19, a member of
the cytochrome P450 monooxygenase family with a
reputation for antiretroviral drug interactions [78], may
lead to a higher availability of abacavir metabolites,
which may in turn trigger the hypersensitivity reaction.
Higher expression of the inflammatory chemokine
CCL1, on the other hand, is associated with so-called
M2b or type 2 alternative monocyte activation [79], and
may thus be indicative of a predisposition to allergic/
hypersensitivity reactions.
An unexplored aspect of this study is an inherent lim-
itation to all transcriptome analyses. In our setup, it
cannot be ascertained to what extent the differential
genes which we identify are dysregulated to a limited
degree in the complete monocyte population or to a
high degree in a limited monocyte subpopulation (such
as only the fraction of infected monocytes in the blood).
However, considering the limited number of infected
monocytes in the peripheral blood, it is likely that the
changes in gene expression which we record here are
the result of external factors on the complete monocyte
population (such as circulating viral antigens or secreted
host-derived factors) rather than direct infection of indi-
vidual monocytes.
In this study of ex vivo monocytes from HIV patients,
we have identified several key areas of cellular dysfunction,
and we have pinpointed multiple genes associated with
both HIV infection and antiretroviral therapy in these key
areas. These genes represent an interesting population for
further in-depth functional studies concerning their role
in HIV pathogenesis. A first candidate for further func-
tional analysis could be the factor NAMPT/visfatin, which
shows a strong correlation with the viral load in patients,
and which seems to mediate an inhibitory effect for HIV
infection in both PBMC and MDM.
Additional material
Additional file 1: Gene collection represented on the custom
Macrophage Activation State array platform. All genes for which
amplified cDNA probes were printed on the custom Macrophage
Activation State array platform are represented; Probe ID: a unique
identifier for each set of gene specific primers used to generate cDNA
probes; OGS: Official Gene Symbol (Entrez Gene); Entrez ID: official Entrez
Gene identifier; Transcript variants: recognition of individual transcript
variants by the cDNA probe, if applicable (All: global probe hybridising
with all known transcript variants; N.A.: no transcript variants known at
time of production).
Additional file 2: Gene specific primer sets for real-time semi-
quantitative PCR. Sequences of gene specific primer sets used in real-
time semi-quantitative PCR are shown; OGS: Official Gene Symbol (Entrez
Gene); Entrez ID: official Entrez Gene identifier.
Additional file 3: Genes expressed differentially in monocytes from
HIV patients versus healthy controls, as assessed by CodeLink HWG
microarray analysis. Samples analysed by CodeLink HWG microarray
were grouped according to HIV serostatus and were analysed for
differential gene expression. Standard CodeLink identifiers are shown
(CodeLink unique probe name, NCBI accession number and NID, Entrez
Gene ID (LocusLink) and UniGene ID); p-val_uncorrected: p-value of
Student’s t test (astringent); p-val_corrected: p-value of Benjamini-
Hochberg corrected Student’s t test (stringent); Fold_change: fold
change between the means of the two groups (HIV/control).
Additional file 4: Differential gene expression in patients with a
beneficial reaction versus a hypersensitivity reaction to abacavir.
Gene expression values as assessed by the Macrophage Activation State
array platform in monocytes of HIV patients who develop the
hypersensitivity reaction to abacavir versus patients with a beneficial
response to the same therapy regimen; gene expression assessed at
baseline before initiation of therapy. Gene expression was mean centred.
Official Gene Symbols are shown, Entrez Gene identification codes are
mentioned in parenthesis.
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